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Abstract
We have prepared a series of new and some literature-reported GABA-amides and determined their effect on the activation of
GABAA-receptors expressed in CHO cells. Special attention was paid to the purification of the target compounds to remove even
traces of GABA contaminations, which may arise from deprotection steps in the synthesis. GABA-amides were previously reported
to be partial, full or superagonists. In our hands these compounds were not able to activate GABAA-receptor channels in whole-cell
patch-clamp recordings. New GABA-amides, however, gave moderate activation responses with a clear structure–activity relation-
ship suggesting some of these compounds as promising molecular tools for the functional analysis of GABAA-receptors.
Introduction
γ-Aminobutyric acid (GABA) is the major inhibitory amino
acid transmitter of the central nervous system (CNS) of verte-
brates (Figure 1).
Figure 1: The neurotransmitter GABA.
It plays an important role in a variety of physiological func-
tions, including motion control, vision, relaxation, sleep and
many other brain functions [1-3]. In vertebrates GABA acti-
vates specific receptors of several classes: GABAA, GABAB
and GABAC [4]. GABAA-receptors are transmembrane
heterooligomeric proteins, forming chloride (Cl−) selective
channels, and are composed of five subunits: two α, two β and
one γ subunit [5]. Being highly expressed in the peripheral and
central nervous system, GABAA-receptors represent a key ther-
Beilstein J. Org. Chem. 2013, 9, 406–410.
407
Scheme 1: Synthesis of GABA-amide hydrochlorides 4a–c and 6a–f. (i) THF, reflux; (ii) MeOH, HCl (5%); (iii) THF, reflux; (iv) MeOH, HCl (5%).
apeutic target for benzodiazepines, barbiturates, neurosteroids
and general anesthetics [6-8]. Therefore, in spite of a large
variety of existing agonists, antagonists and modulators of
GABA-receptors, there is a high interest in the development of
new drugs that can interact with these targets. Many com-
pounds of different substance classes are known to modulate the
activity of GABAA-receptors [9-12]. One substance group that
has been less explored is GABA-amides. Compounds 4a, 4b,
4c, 7a (as triflate salt) and 7c were previously reported to
potently activate the GABAA-channels, being "partial, full or
superagonists" [13]. However, in their work the authors studied
the activity of GABA-amides on GABAA-receptors using chlo-
ride-flux assays on synaptoneurosomes. Such preparations can
contain many damaged cells leading to a highly variable intra-
cellular Cl− distribution in different cells. In our study we used
the patch-clamp technique, which is much more reliable and
informative in comparison to the approach based on chloride-
flux assays. Like Carlier et al. [13], we noticed that in the
course of the GABA-amide synthesis, GABA impurities are
generated in the deprotection step. However, in contrast to
Carlier et al. [13], who used a modification of Sallers’s proce-
dure [14] (detection limit <0.1 wt %) to check the purity of the
compounds, we developed an improved purification procedure
and used a more sensitive HPLC–MS analysis to ensure that the
GABA-amide products do not contain any detectable amount of
GABA (detection limit <0.002 wt %). Our observations may
help to give a more complete picture of the ability of GABA-
amides to activate GABAA receptors.
Results and Discussion
Boc-Pyrrolidone 1 was nucleophilic-ring-opened by diamines
2a–c or the mono Boc-protected diamines 5a–f in THF
(Scheme 1, See Supporting Information File 1 for full experi-
mental data).
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To cleave the Boc-protecting groups, the compounds were
dissolved in dilute HCl (5%, EtOH/H2O). It was observed that
the use of more concentrated HCl can cause cleavage of the
amide bonds and the release of free GABA. To remove any
impurities of GABA, which may lead to false test results, all
substances were carefully purified: In a first purification step
the GABA-amide hydrochlorides were dissolved in MeOH and
precipitated by slow addition of Et2O. The precipitates were
centrifuged and recrystallized several times from MeOH until
no traces of GABA could be detected by HPLC–MS analysis.
To determine the sensitivity of the analysis method three stock
solutions of GABA were prepared (10−3, 10−5 and 10−7 mol/L)
and 1 µL was injected into the HPLC-coupled mass spectrom-
eter. On the basis of the obtained mass spectra, a GABA detec-
tion limit of 0.14 pmol (14 pg) was determined.
By examining the Cl− uptake elicited by different GABAA-
receptor agonists, Carlier et al. demonstrated that compounds
with general structure 4a–c were capable of stimulating Cl−
uptake with different efficacy [13]. Moreover, the authors
described compound 4b as "superagonist", because it induced a
maximum uptake about 50% higher than that achieved by
GABA. Surprisingly, the EC50 value for this compound was
more than 30-fold higher than for GABA, i.e., at 733 µM and
14.3 µM, respectively. The investigations in this study were
performed by using a standard 36Cl−-flux assay in mouse brain
synaptoneurosomes. This technique does not allow a compara-
tive analysis on one cell. Moreover, 36Cl−-flux assays were
carried out by using a 15 s incubation time. As GABA-recep-
tors usually exhibit strong desensitization at long exposures to
agonists, we decided to re-examine these results using patch-
clamp recordings and fast perfusion technique for the applica-
tion of the tested compounds. The activity of synthesized com-
pounds was tested by using CHO cells transiently expressing
GABAA-receptors in the configuration (α1-GFP + β2 + γ2Long).
To analyze the functional properties of the compounds, we
performed monitoring of ionic currents using whole-cell patch-
clamp techniques. First, concentration-response curves for
GABA were obtained and its EC50 was determined. Then we
applied different concentrations of the studied compounds and
estimated the minimal concentration that induced currents and,
if possible, their EC50. The EC50 for GABA varied in different
cells from 4 µM to 15 µM with a mean of 9.5 ± 0.3 µM
(x [number of tested cells] = 10) (Figure 2, see Supporting
Information File 1 for full experimental data).
Surprisingly, in contrast to previously described observations,
our purified compounds 4a–c were not able to activate
GABAA-receptors in concentrations up to 10 mM. Figure 3
illustrates this for the compound 4c. Similar results were
obtained also for compounds 4a and 4b: on application of
Figure 2: Effect of 7b on GABAA-receptor activation. (A) Superim-
posed traces of whole-cell currents induced by rapid application of
GABA (left) or compound 7b (right) in CHO cells transfected with
α1-GFP/β/γ2L combination of GABAA receptor subunits; (B) Concentra-
tion dependencies of GABA (closed squares) and 7b (closed circles).
EC50s were 12 µM and 10 mM for GABA and 7b, respectively.
Figure 3: Absence of GABAA-receptor activation on application of 4c.
Top traces: Examples of whole-cell currents on rapid application of 4c
on CHO cells transfected with an α1-GFP/β2/γ2L combination of
GABAA-receptor subunits. Note that the compound was not able to in-
duce currents even at a concentration of 15 mM.
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Figure 5: Effect of 7d on GABAA-receptor activation. (A,B) Superimposed traces of whole-cell currents induced by rapid application of GABA (A) or
the compound 7d (B) in CHO cells transfected with an α1-GFP/β2/γ2L combination of GABAA-receptor subunits; (C) Concentration dependencies
obtained on application of GABA (red closed square) and 7d (black closed circles). EC50 values were 10.2 µM and 5.1 mM for GABA and 7d, respect-
ively; (D) Current–voltage relations for responses induced by compound 7d. Insert: examples of traces at different membrane potentials. Scales: 2 nA
and 1 s.
10 mM, the changes in the current were 0 pA, (x = 4 for each
compound).
In contrast, all studied compounds from series 7a–e were
capable of inducing ionic currents with different efficacy
(Figure 4).
Thus, compound 7a (n = 2) activated currents at 2.6 mM with
an amplitude of 10–30 pA (x = 4). The compound 7b (n = 3)
activated GABA-receptors more strongly and at concentrations
of 10 mM induced currents comparable to those for GABA
30–100 µM (Figure 2). The EC50 for compound 7b is
1080 ± 140 µM (x = 4). The efficacy of the compounds is
significantly weaker than for GABA. The number of -CH2-units
between the amide nitrogen atom and the ammonium moiety of
compounds 7 affects the efficacy significantly, reaching a
maximum with compound 7c (n = 4). The EC50 for compound
7c is 1750 ± 330 µM (x = 7). Compound 7d (n = 6) also effec-
tively activated GABAA-receptors with an activation threshold
of about 100 µM. At concentrations of 10 mM it caused
currents similar of those induced by saturated GABA concentra-
tions (30–100 µM) with an EC50 of about 5 mM (Figure 5A–C).
The EC50 for compound 7d is 5250 ± 560 µM (x = 6). Kinetics
Figure 4: Variation of EC50 values with the number n of methylene
units separating the amide and the ammonium group in compounds
7a–e. Each column represents results from 3–7 cells. The mark [?] on
the top of bars indicates that for the EC50‘s for these compounds were
not determined precisely.
of desensitization and the current–voltage dependencies
(Figure 5D) of the studied compounds are similar to those for
GABA. Compound 7e (n = 8) weakly activated currents at
5 mM with an amplitude of 10–20 pA (x = 3).
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Conclusion
Our data suggest that compounds 4a–c are not capable of acti-
vating GABAA-receptors. Compounds 7a–e are able to stimu-
late these receptors and show a distinct structure–activity corre-
lation. The compounds may become useful as molecular tools
for the functional analysis of GABAA-receptors.
Supporting Information
Exact synthetic procedures, copies of 1H NMR and
HPLC–MS spectra of GABA-amide hydrochlorides 4a–c
and 7a–f. Cell culture, transient transfection methods and
electrophysical recordings.
Supporting Information File 1
Experimental part.
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